Tag: Dr. Isa Odidi
November 27, 2018
Intellipharmaceutics Submits Investigational New Drug Application to the U.S. FDA for IPCI006 (oxycodone hydrochloride immediate release) Tablets Incorporating its Abuse Deterrent and Overdose Resistant Technology
Intellipharmaceutics International Inc. (NASDAQ and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of... January 24, 2018
Intellipharmaceutics Provides Operational Update
Intellipharmaceutics International (Nasdaq:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release...
December 13, 2017
5 Top Pharmaceutical Stories of 2017
Here are the five top stories that caught the attention of our investor audience in the pharmaceutical business during 2017. April 10, 2017
Intellipharmaceutics To Challenge Patent Lawsuit
Intellipharmaceutics International is facing legal action related to a patent infringement case from Purdue Pharma.
March 20, 2017